 NEW YORK--BUSINESS WIRE--Schrödinger, Inc. Nasdaq: SDGR, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor, SGR-2921, will be presented during a poster session at the American Society of Hematology ASH 64th Annual Meeting taking place virtually and in New Orleans, Louisiana, December 10-13, 2022. 